Users' guides to the medical literature: XII. How to use articles about health-related quality of life

JAMA

Volumn 277, Issue 15, 1997, Pages 1232-1237

  Guyatt, Gordon H ^a   Naylor, C David ^b   Juniper, Elizabeth ^a   Heyland, Daren K ^a   Jaeschke, Roman ^a   Cook, Deborah J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH; LIFE; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0030896241     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.15.1232     Document Type: Review

References (50)

1. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life: basic sciences review. Ann Intern Med. 1993;70:225-230.
3. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619-626.
4. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273:59-65.
5. Guyatt GH, Cook DJ. Health status, quality of life, and the individual. JAMA. 1994;272:630-631.
6. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy to hypoxemic chronic obstructive lung disease. Ann Intern Med. 1980;93:391-398.
7. Heaton RK, Grant I, McSweeney AJ, Adams KM, Petty TL. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1983;143:1941-1947.
8. Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez G. Relative efficacy of vasodilator therapy in chronic congestive heart failure: implications of randomized trials. JAMA. 1988;259:3422-3426.
9. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
10. Pak CY, Sakhaee K, Piziak V, et al. Slow-release sodium fluoride in the management of post-menopausal osteoporosis. Ann Intern Med. 1994;120:625-632.
11. Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 1993;36:750-756.
12. Guyatt GH, Thompson PJ, Herman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis. 1985;38:517-524.
13. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interob-server agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-758.
14. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure, II: content, reliability and validity of a new measure - the Minnesota Living With Heart Failure Questionnaire. Heart Failure. 1987;3:198-209.
15. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:468-479.
16. Wiklund I, Comerford MB, Dimenas E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol. 1991;14:204-208.
17. Osteoporosis Quality of Life Research Group. Measuring quality of life in women with osteoporosis. J Bone Miner Res. In press.
18. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773-778.
19. Goldstein RS, Gort EH, Guyatt GH, Stubbing D, Avendano MA. Prospective randomized controlled trial of respiratory rehabilitation. Lancet. 1994;344:1394-1397.
20. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995:332:75-79.
21. Guyatt GH, Mitchell A, Iryine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810.
22. Kirshner B, Guyatt GH. A methodologic framework for assessing health indices. J Chronic Dis. 1985;38:27-36.
23. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol. 1992:45:1341-1345.
24. De Weerdt I, Visser AP, Kok GI, de Weerdt O, Van der Veen EA. Randomized controlled multicentre evaluation of an education programme for insulin-treated diabetic patients: effects on metabolic control, quality of life, and costs of therapy. Diabet Med. 1991;8:338-345.
25. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287-296.
26. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836-841.
27. Salonen R, Ashford E, Dahlof C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol. 1994;241:463-469.
28. Mathew NT, Saper JR, SUberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
29. Trying S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med. 1995;123:89-96.
30. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cydosporin and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cydosporine Combination Study Group. N Engl J Med. 1995;333:137-141.
31. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the Arthritis and Rheumatism Council Low-Dose Glucoeorticoid Study Group. N Engl J Med. 1995;333:142-146.
32. Malmivaara A, Hakkinen U, Aro T, et al. The treatment of acute low back pain: bed rest, exercises, or ordinary activity. N Engl J Med. 1995;332:351-355.
33. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
34. Tarlov AR, Ware JE Jr, Greenfield S, Nelson EC, Perrin E, Zubkoff M. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA. 1989;262:925-930.
35. Ware JE, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results of the Medical Outcomes Study. Med Care. 1995;33;AS264-AS279.
36. Tandon PK, Stander H, Schwarz RP Jr. Analysis of quality of life data from a randomized, placebo controlled heart-failure trial. J Clin Epidemiol. 1989;42:955-962.
37. Smith D, Baker G, Daviea G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34:312-322.
38. Chang SW, Fine R, Siegel D, Chesney M, Black D, Hulley SB. The impact of diuretic therapy on reported sexual function. Arch Intern Med. 1991;151:2402-2408.
39. Tugwell P, Bombardier C, Buchanan WW, et al. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med. 1990;150:59-62.
40. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. Control Clin Trials. 1991;12:168S-179S.
41. Boyle MH, Torrance GW, Sinclair JC, Horwood SJ. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med. 1983;308:1330-1337.
42. Hornberger JC, Garber AM, Chemew ME. Is high-flux dialysis cost-effective? Int J Technol Assess Health Care. 1993;985-96.
43. Hornberger JC. The hemodialysis prescription and cost effectiveness. J Am Soc Nephrol. 1993;4:1021-1027.
44. Naylor CD. Cost-effectiveness analysis: are the outputs worth the inputs? ACP J Club. 1996;124:a12-a14.
45. Testa MA, Anderson RB, Nackley JF, Hollenberg NK, for the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Engl J Med. 1993;328:907-913.
46. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-87.
47. Redelmeier DA, Goldstein RS, Guyatt GH. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49:1215-1219.
48. Jaeschke R, Guyatt G, Keller J, Singer J. Measurement of health status: ascertaining the meaning of a change in quality-of-life questionnaire score. Control Clin Trials. 1989;10:407-415.
49. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35-46.
50. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroentrol. 1988;10:306-310.